<DOC>
	<DOCNO>NCT00189150</DOCNO>
	<brief_summary>The primary objective study determine whether clinically significant PK drug interaction ( 30 % difference AUC MPA ) exist mycophenolate mofetil ( steady state condition ) VGCV renal cardiac transplant recipient . This study provide clinically relevant information transplant community . It clearly delineate whether clinically significant PK drug interaction exist mycophenolate mofetil ( steady-state condition ) VGCV . Given establish dose/efficacy relationship MMF VGCV , study provide improve dosing guideline potentially avoid adverse outcome due empiric dosage adjustment .</brief_summary>
	<brief_title>Pharmacokinetics Mmf Valganciclovir</brief_title>
	<detailed_description>Mycophenolate mofetil ( immunosuppressant , MMF ) valganciclovir ( antiviral , VGCV ) commonly administer together transplant patient . Following oral administration , MMF VGCV metabolize active form , mycophenolic acid ( MPA ) gancoclovir ( GCV ) respectively . Both MPA GCV eliminate kidney renal excretion , data MPA pharmacokinetic parameter affect GCV steady state condition . Both MPA GCV cause neutropenia although unsubstantiated , clinician observe increased occurrence neutropenia agent use combination . In presence neutropenia , practitioner often challenge make decision regard whether dosage one agent reduce . It would useful know whether neutropenia due increase drug concentration whether due direct effect agents bone marrow .</detailed_description>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>The subject must able give informed consent study . Stable renal cardiac transplant patient age 18 year old . Patients must acute rejection episode within previous 30 day 1st PK study . Renal transplant patient serum creatinine &lt; 2 mg/dL change serum creatinine &lt; 25 % within 2 week prior 1st PK study . Renal cardiac transplant patient receive VGCV prophylaxis CMV concomitantly receive MMF . Stable MMF dose : dose MMF must adjust within 1 week 1st PK study must 2nd PK study Stable renal function study period ( change serum creatinine &lt; 25 % ) Patients prescribed MMF maintenance therapy receive Myfortic . Patients require VGCV prophylaxis ( CMV negative recipient CMV negative donor organ ) . Patients MMF dos adjust either &lt; 1 week 1st schedule PK study anytime study period . Patients whose serum creatinine change &gt; 25 % within 2 week prior study initiation . Patients whose hematocrit &lt; 28 % . Patients receive organ transplant addition kidney heart . Patients pregnant breastfeeding . Patients prescribe bile acid , bile acid sequestrants , potassium binding resin , magnesium/aluminumcontaining antacid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Valganciclovir</keyword>
	<keyword>Mycophenolate Mofetil</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Interaction</keyword>
	<keyword>MPA</keyword>
</DOC>